Investors

Financials & Filings

Filing date Form Description Filing Group View
8-K

Report of unscheduled material events or corporate event

Current Reports
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
8-K

Report of unscheduled material events or corporate event

Current Reports
8-K

Report of unscheduled material events or corporate event

Current Reports
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements
S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements
4/A

Amendment to a previously filed 4

3,4,5

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.